Alcobra names new board member
This article was originally published in Scrip
Executive Summary
Tel Aviv, Israel-based Alcobra, an emerging pharmaceutical company focused on the development of new medications for cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, has appointed Dr Joao Siffert to its board of directors. Dr Siffert is currently executive vice-president of R&D and chief medical officer of Avanir Pharmaceuticals (a subsidiary of Otsuka Pharmaceutical).
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.